Innovent Biologics Technology Limited
Clinical trials sponsored by Innovent Biologics Technology Limited, explained in plain language.
A Chinese biopharmaceutical company developing and commercializing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye injection shows promise for Diabetes-Related vision loss Results expected Dec 2026 (estimated)
- New hope for advanced tumors? early trial of IBI3026 begins Results expected Dec 2026 (estimated)
- Could a new pill beat the standard for gout? large trial underway Results expected Apr 2027 (estimated)
-
New Weight-Loss pill enters human testing
Disease control CompletedThis early-stage trial tests the safety of a new oral drug, IBI3032, in 104 people. Part A gives a single dose to healthy volunteers, while Part B gives multiple doses over 4 weeks to people with overweight or obesity. The goal is to check for side effects and how the drug moves …
Phase 1 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug IBI3032 tested for safety in small human study
Knowledge-focused CompletedThis early-phase trial tested the safety and how the body handles a single dose of IBI3032 in 40 healthy adults. Participants were randomly assigned to receive either IBI3032 or a placebo, and some groups also looked at the effect of food on the drug. The study is complete and fo…
Early phase 1 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC